צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: SELLAS Life Sciences (SLS)

SELLAS Life Sciences relies on patent protection for immunotherapeutic vaccines to generate royalties and cash flow. The trailing twelve months (TTM) operating revenue growth reflects revenue dynamics, with the indicator recorded at 0.00. Ownership of formulas enables large-scale production at low costs, yet a critical liquidity shortage and the risks of clinical trial failure create a threat of delisting.

This indicator measures the relative change in revenue over the last twelve months, allowing investors to identify the moment of stabilization or reversal of cash flows through the YoY revenue growth trend for TTM. For SELLAS Life Sciences (SLS), whose model is based on outsourcing the development of cancer vaccines, this metric is critical as it reflects the commercial efficiency of patent management in the absence of in-house production facilities.